|
Pegaspargase Clinical Trials
11 actively recruiting trials across 3 locations
▼ -2 trials since May 2026
Also known as: L-Asparaginase with Polyethylene Glycol, Oncaspar, Oncaspar-IV, PEG, PEG-Asparaginase +6 more
Pipeline
Phase 1: 1Phase 2: 6Phase 3: 2Phase 4: 1Phase 1/2: 1
Top Sponsors
- National Cancer Institute (NCI)2
- Children's Oncology Group2
- Wei Zhao1
- University of Chicago1
- Martin Schrappe1
Indications
- Cancer11
- Recurrent B Acute Lymphoblastic Leukemia2
- T-lymphoblastic Lymphoma2
- B Acute Lymphoblastic Leukemia2
- Refractory B Lymphoblastic Lymphoma1
Other5 trials
Birmingham, Alabama4 trials
Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Children's Hospital of Alabama
Phase 2
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Hospital of Alabama
Phase 3
Chicago, Illinois1 trial
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
University of Chicago Medical Center
Phase 1
Houston, Texas1 trial
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M D Anderson Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.